Literature DB >> 12381789

Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.

Katrina K Hoyer1, Samuel W French, Devin E Turner, Mai T N Nguyen, Mathilde Renard, Cindy S Malone, Sonja Knoetig, Chen-Feng Qi, Thomas T Su, Hilde Cheroutre, Randolph Wall, David J Rawlings, Herbert C Morse, Michael A Teitell.   

Abstract

The TCL1 protooncogene is overexpressed in many mature B cell lymphomas, especially from AIDS patients. To determine whether aberrant expression promotes B cell transformation, we generated a murine model in which a TCL1 transgene was overexpressed at similar levels in both B and T cells. Strikingly, transgenic mice developed Burkitt-like lymphoma (BLL) and diffuse large B cell lymphoma (DLBCL) with attendant Bcl-6 expression and mutated J(H) gene segments at a very high penetrance beginning at 4 months of age. In contrast, only one mouse developed a T cell malignancy at 15 months, consistent with a longer latency for transformation of T cells by TCL1. Activation of premalignant splenic B cells by means of B cell antigen receptor (BCR) engagement resulted in significantly increased proliferation and augmented AKT-dependent signaling, including increased S6 ribosomal protein phosphorylation. Transgenic spleen cells also survived longer than wild-type spleen cells in long-term culture. Together these data demonstrate that TCL1 is a powerful oncogene that, when overexpressed in both B and T cells, predominantly yields mature B cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381789      PMCID: PMC137894          DOI: 10.1073/pnas.212410199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  The protooncogene TCL1 is an Akt kinase coactivator.

Authors:  J Laine; G Künstle; T Obata; M Sha; M Noguchi
Journal:  Mol Cell       Date:  2000-08       Impact factor: 17.970

Review 2.  Ribosomal S6 kinase signaling and the control of translation.

Authors:  A Dufner; G Thomas
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

3.  T cell progenitors emerge earlier than B cell progenitors in the murine fetal liver.

Authors:  H Kawamoto; T Ikawa; K Ohmura; S Fujimoto; Y Katsura
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

4.  Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1.

Authors:  M Collado; R H Medema; I Garcia-Cao; M L Dubuisson; M Barradas; J Glassford; C Rivas; B M Burgering; M Serrano; E W Lam
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  The T-cell receptor regulates Akt (protein kinase B) via a pathway involving Rac1 and phosphatidylinositide 3-kinase.

Authors:  E M Genot; C Arrieumerlou; G Ku; B M Burgering; A Weiss; I M Kramer
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

6.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Authors:  M Bärlund; F Forozan; J Kononen; L Bubendorf; Y Chen; M L Bittner; J Torhorst; P Haas; C Bucher; G Sauter; O P Kallioniemi; A Kallioniemi
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

7.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.

Authors:  L Pasqualucci; A Migliazza; N Fracchiolla; C William; A Neri; L Baldini; R S Chaganti; U Klein; R Küppers; K Rajewsky; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

8.  Tcl1 enhances Akt kinase activity and mediates its nuclear translocation.

Authors:  Y Pekarsky; A Koval; C Hallas; R Bichi; M Tresini; S Malstrom; G Russo; P Tsichlis; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

9.  Burkitt lymphoma in the mouse.

Authors:  A L Kovalchuk; C F Qi; T A Torrey; L Taddesse-Heath; L Feigenbaum; S S Park; A Gerbitz; G Klobeck; K Hoertnagel; A Polack; G W Bornkamm; S Janz; H C Morse
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

10.  Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.

Authors:  M G Narducci; E Pescarmona; C Lazzeri; S Signoretti; A M Lavinia; D Remotti; E Scala; C D Baroni; A Stoppacciaro; C M Croce; G Russo
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

View more
  32 in total

1.  Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma.

Authors:  Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Josep Nomdedeu; Miguel Angel Pavón; Iñigo Espinosa; Maria Antònia Mangues; Jorge Sierra; Isolda Casanova; Ramon Mangues
Journal:  Clin Exp Metastasis       Date:  2012-01-20       Impact factor: 5.150

2.  Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor.

Authors:  Yair Benita; Zhifang Cao; Cosmas Giallourakis; Chun Li; Agnès Gardet; Ramnik J Xavier
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

Review 3.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

4.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Authors:  Jinsheng Weng; Seema Rawal; Fuliang Chu; Hyun Jun Park; Rakesh Sharma; David A Delgado; Luis Fayad; Michelle Fanale; Jorge Romaguera; Amber Luong; Larry W Kwak; Sattva S Neelapu
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

5.  MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Authors:  Luciano Mazzoccoli; Marcela Cristina Robaina; Alexandre Gustavo Apa; Martin Bonamino; Luciana Wernersbach Pinto; Eduardo Queiroga; Carlos E Bacchi; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-09       Impact factor: 4.553

6.  EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.

Authors:  Francesco Boccellato; Eleni Anastasiadou; Paola Rosato; Bettina Kempkes; Luigi Frati; Alberto Faggioni; Pankaj Trivedi
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

7.  Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages.

Authors:  Uma K Misra; Steven J Kaczowka; Salvatore V Pizzo
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

Review 8.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

9.  Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Authors:  Matthew J Frank; David W Dawson; Steven J Bensinger; Jason S Hong; Wendy M Knosp; Lizhong Xu; Cynthia E Balatoni; Eric L Allen; Rhine R Shen; Dafna Bar-Sagi; Gail R Martin; Michael A Teitell
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

10.  Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.

Authors:  Giorgio Cattoretti; Jonathan Mandelbaum; Nancy Lee; Alicia H Chaves; Ashley M Mahler; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci; A John MacLennan
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.